[1]
|
Wu, M., Tian, Y., Wang, Q. and Guo, C. (2020) Gout: A Disease Involved with Complicated Immunoinflammatory Responses: A Narrative Review. Clinical Rheumatology, 39, 2849-2859. https://doi.org/10.1007/s10067-020-05090-8
|
[2]
|
Luk, A.J. and Simkin, P.A. (2005) Epidemiology of Hyperuricemia and Gout. The American Journal of Managed Care, 11, S435-S442; quiz S65-S68.
|
[3]
|
Mackenzie, I.S., Ford, I., Nuki, G., Hallas, J., Hawkey, C.J., Webster, J., et al. (2020) Long-Term Cardiovascular Safety of Febuxostat Compared with Allopurinol in Patients with Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, Non-Inferiority Trial. Lancet, 396, 1745-1757. https://doi.org/10.1016/S0140-6736(20)32234-0
|
[4]
|
Sniderman, A.D., Thanassoulis, G., Glavinovic, T., Navar, A.M., Pencina, M., Catapano, A., et al. (2019) Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 4, 1287-1295.
https://doi.org/10.1001/jamacardio.2019.3780
|
[5]
|
Benn, M., Nordestgaard, B.G., Jensen, G.B. and Tybjaerg-Hansen, A. (2007) Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B: The Copenhagen City Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 661-670. https://doi.org/10.1161/01.ATV.0000255580.73689.8e
|
[6]
|
Johannesen, C.D.L., Mortensen, M.B., Langsted, A. and Nordestgaard, B.G. (2021) Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology, 77, 1439-1450. https://doi.org/10.1016/j.jacc.2021.01.027
|
[7]
|
Kuo, C.F., Grainge, M.J., Zhang, W. and Doherty, M. (2015) Global Epidemiology of Gout: Prevalence, Incidence and Risk Factors. Nature Reviews Rheumatology, 11, 649-662. https://doi.org/10.1038/nrrheum.2015.91
|
[8]
|
Primatesta, P., Plana, E. and Rothenbacher, D. (2011) Gout Treatment and Comorbidities: A Retrospective Cohort Study in a Large US Managed Care Population. BMC Musculoskeletal Disorders, 12, Article No. 103.
https://doi.org/10.1186/1471-2474-12-103
|
[9]
|
Zheng, X., Gong, L., Luo, R., Chen, H., Peng, B., Ren, W., et al. (2017) Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Non-Obesity Chinese Adults. Lipids in Health and Disease, 16, Article No. 202.
https://doi.org/10.1186/s12944-017-0531-5
|
[10]
|
Chen-Xu, M., Yokose, C., Rai, S.K., Pillinger, M.H. and Choi, H.K. (2019) Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis & Rheumatology, 71, 991-999. https://doi.org/10.1002/art.40807
|
[11]
|
Dehlin, M. and Jacobsson, L. (2020) Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. Nature Reviews Rheumatology, 16, 380-390. https://doi.org/10.1038/s41584-020-0441-1
|
[12]
|
Safiri, S., Kolahi, A.A., Cross, M., Carson-Chahhoud, K., Hoy, D., Almasi-Hashiani, A., et al. (2020) Prevalence, Incidence, and Years Lived with Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis & Rheumatology, 72, 1916-1927. https://doi.org/10.1002/art.41404
|
[13]
|
Cohen, R.E. and Pillinger, M.H. (2020) Something Old, Something New: the ACR Gout Treatment Guideline and Its Evolution from 2012 to 2020. Current Rheumatology Reports, 23, Article No. 4.
https://doi.org/10.1007/s11926-020-00967-8
|
[14]
|
Stamp, L.K. and Chapman, P.T. (2013) Gout and Its Comorbidities: Implications for Therapy. Rheumatology, 52, 34-44. https://doi.org/10.1093/rheumatology/kes211
|
[15]
|
Takahashi, S., Yamamoto, T., Moriwaki, Y., Tsutsumi, Z. and Higashino, K. (1994) Impaired Lipoprotein Metabolism in Patients with Primary Gout—Influence of Alcohol Intake and Body Weight. British Journal of Rheumatology, 33, 731-734. https://doi.org/10.1093/rheumatology/33.8.731
|
[16]
|
Rasheed, H., Hsu, A., Dalbeth, N., Stamp, L.K., McCormick, S. and Merriman, T.R. (2014) The Relationship of Apolipoprotein B and Very Low Density Lipoprotein Triglyceride with Hyperuricemia and Gout. Arthritis Research & Therapy, 16, Article No. 495. https://doi.org/10.1186/s13075-014-0495-z
|
[17]
|
Carr, S.S., Hooper, A.J., Sullivan, D.R. and Burnett, J.R. (2019) Non-HDL-Cholesterol and Apolipoprotein B Compared with LDL-Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment. Pathology, 51, 148-154.
https://doi.org/10.1016/j.pathol.2018.11.006
|
[18]
|
Jialal, I. (1996) A Practical Approach to the Laboratory Diagnosis of Dyslipidemia. American Journal of Clinical Pathology, 106, 128-138. https://doi.org/10.1093/ajcp/106.1.128
|
[19]
|
Goldstein, J.L. and Brown, M.S. (2015) A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161, 161-172. https://doi.org/10.1016/j.cell.2015.01.036
|
[20]
|
Skålén, K., Gustafsson, M., Rydberg, E.K., Hultén, L.M., Wiklund, O., Innerarity, T.L., et al. (2002) Subendothelial Retention of Atherogenic Lipoproteins in Early Atherosclerosis. Nature, 417, 750-754.
https://doi.org/10.1038/nature00804
|
[21]
|
Libby, P., Loscalzo, J., Ridker, P.M., Farkouh, M.E., Hsue, P.Y., Fuster, V., et al. (2018) Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 72, 2071-2081. https://doi.org/10.1016/j.jacc.2018.08.1043
|
[22]
|
Welsh, C., Celis-Morales, C.A., Brown, R., Mackay, D.F., Lewsey, J., Mark, P.B., et al. (2019) Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 140, 542-552. https://doi.org/10.1161/CIRCULATIONAHA.119.041149
|
[23]
|
Pencina, M.J., D’Agostino, R.B., Zdrojewski, T., Williams, K, Thanassoulis, G., Furberg, C.D., et al. (2015) Apolipoprotein B Improves Risk Assessment of Future Coronary Heart Disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 22, 1321-1327.
https://doi.org/10.1177/2047487315569411
|
[24]
|
Wilkins, J.T., Li, R.C., Sniderman, A., Chan, C. and Lloyd-Jones, D.M. (2016) Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study. Journal of the American College of Cardiology, 67, 193-201. https://doi.org/10.1016/j.jacc.2015.10.055
|
[25]
|
Meeusen, J.W., Donato, L.J. and Jaffe, A.S. (2016) Should Apolipoprotein B Replace LDL Cholesterol as Therapeutic Targets Are Lowered? Current Opinion in Lipidology, 27, 359-366. https://doi.org/10.1097/MOL.0000000000000313
|
[26]
|
White, W.B., Saag, K.G., Becker, M.A., Borer, J.S., Gorelick, P.B., Whelton, A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210.
https://doi.org/10.1056/NEJMoa1710895
|
[27]
|
Thottam, G.E., Krasnokutsky, S. and Pillinger, M.H. (2017) Gout and Metabolic Syndrome: A Tangled Web. Current Rheumatology Reports, 19, Article No. 60. https://doi.org/10.1007/s11926-017-0688-y
|
[28]
|
Abbott, R.D., Brand, F.N., Kannel, W.B. and Castelli, W.P. (1988) Gout and Coronary Heart Disease: The Framingham Study. Journal of Clinical Epidemiology, 41, 237-242. https://doi.org/10.1016/0895-4356(88)90127-8
|
[29]
|
Edwards, N.L. (2009) The Role of Hyperuricemia in Vascular Disorders. Current Opinion in Rheumatology, 21, 132-137. https://doi.org/10.1097/BOR.0b013e3283257b96
|
[30]
|
Agabiti-Rosei, E. and Grassi, G. (2013) Beyond Gout: Uric Acid and Cardiovascular Diseases. Current Medical Research and Opinion, 29, 33-39. https://doi.org/10.1185/03007995.2013.790804
|
[31]
|
Thanassoulis, G., Brophy, J.M., Richard, H. and Pilote, L. (2010) Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine, 170, 1358-1364. https://doi.org/10.1001/archinternmed.2010.198
|
[32]
|
Chen, J.H., Lan, J.L., Cheng, C.F., Liang, W.M., Lin, H.Y., Tsay, G.J., et al. (2015) Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study. PLoS ONE, 10, e0145193. https://doi.org/10.1371/journal.pone.0145193
|
[33]
|
Chen, J.H., Lan, J.L., Cheng, C.F., Liang, W.M., Lin, H.Y., Tsay, G.J., et al. (2015) Effect of Urate-Lowering Therapy on the Risk of Cardiovascular Disease and All-Cause Mortality in Patients with Gout: A Case-Matched Cohort Study. The Journal of Rheumatology, 42, 1694-1701. https://doi.org/10.3899/jrheum.141542
|